Trial Profile

A randomized sequence, single-centre, open label, 5-period crossover, phase 1 comparative bioavailability study to determine the relative bioavailability and absorption characteristics of four investigational formulations of OX640 versus an intramuscular auto-injector of epinephrine in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2024 Results assessing bioavailability and stability of an epinephrine nasal powder formulation for treatment of anaphylaxis presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
11 Oct 2022 Results presented in an Orexo Media Release.
08 Jul 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com